Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Drug Profile

Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Alternative Names: CTLA-4 Probody Tx; CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 25 Jul 2017 Cytomx Therapeutics plans a clinical trial for the CTLA-4 directed Probody in early 2018 (Cytomx Therapeutics pipeline, July 2017)
  • 20 Mar 2017 Bristol-Myers-Squibb and CytomX expand their worldwide licensing agreement for protease-activated monoclonal antibodies
  • 12 Jan 2017 Discontinued for Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top